Benitec Biopharma Inc.BNTCNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | -185.85% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +23.37% | +114.32% | +269.85% | +259.00% | +290.07% |
| Weighted Average Shares Diluted Growth | +23.37% | +114.21% | +268.84% | +259.00% | +290.07% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -92.45% | -96.23% | -94.34% | -85.59% | +75.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +154.22% | +270.29% | +601.44% | +90.75% | +39.63% |
| Book Value per Share Growth | +133.20% | +129.04% | +129.40% | -42.64% | -62.61% |
| Debt Growth | -57.03% | -67.61% | +170.90% | +198.94% | +287.20% |
| R&D Expense Growth | -19.06% | -0.59% | +133.05% | +5.21% | +42.22% |
| SG&A Expenses Growth | +36.36% | +89.53% | +175.67% | +593.11% | +351.72% |